Ecto-5′-Nucleotidase Activity in Human T Cell Subsets. DECREASED NUMBERS OF ECTO-5′-NUCLEOTIDASE POSITIVE CELLS FROM BOTH OKT4+ AND OKT8+ CELLS IN PATIENTS WITH HYPOGAMMAGLOBULINEMIA

Thompson, Linda F.; Saxon, Andrew; O’Connor, Richard D.; Fox, Robert I.

doi:10.1172/jci110843

Cited by 36 publications

(2 citation statements)

References 46 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5NT deficiency has been observed in peripheral blood lymphocytes from patients with hypogammaglobulinemia [41,65] and X-linked congenital agammaglobulinemia [75,76]. However, the 5NT deficiency in these patients is probably a consequence of celt immaturity and not the cause.…”

Section: Ecto-5'-nucleotidase (5nt)mentioning

confidence: 99%

“…The enzymatic changes during development in the thymus might account for the clonal selection of those T-cells which recognize themselves by preventing the build-up of dATP [50]. Among normal T-cell subpopulations 5NT activity is significantly higher in T suppressor/cytotoxic (OKT8 +) cells than in T-helper/inducer (OKT4 +) cells [52,76].…”

Section: Normal and Neoplastic T-cellsmentioning

confidence: 99%

See 1 more Smart Citation

Enzymes of purine metabolism in lymphoid neoplasms, clinical relevance for treatment with enzyme inhibitors

Ganeshaguru

1988

Klin Wochenschr

View full text Add to dashboard Cite

A few enzymes of the purine degradative pathway have proved valuable in diagnosis and treatment of lymphomas and lymphocytic leukemia. Of particular interest are the enzymes adenosine deaminase (ADA), purine nucleoside phosphorylase (PNP) and ecto-5'-nucleotidase (5NT). Intact activities of ADA and PNP have been shown to be vital for lymphoid cells. During development, lymphoid precursors go through remarkable changes in the concentrations of these enzymes and the neoplasms derived from them show a "frozen" biochemical profile similar to the corresponding normal cell of origin. Knowledge of the role of these enzymes has led to the pharmacological use of enzyme inhibitors for the specific treatment of lymphoid neoplasms. This review concerns the enzymatic make-up of normal and neoplastic lymphocytes and exploitation of this knowledge for the treatment of lymphomas. Special emphasis will be put on the clinical use of an ADA-inhibitor, deoxycoformycin.

show abstract

Section: Ecto-5'-nucleotidase (5nt)mentioning

confidence: 99%

Section: Normal and Neoplastic T-cellsmentioning

confidence: 99%